09/03/2026
The FDA is asking a question that every medical-AI developer—and every healthcare leader—should take seriously:
Should generative AI-enabled medical devices be evaluated for competency in much the same way clinicians are?
Last month, the FDA’s Center for Devices and Radiological Health released a discussion paper addressing generative AI-enabled medical devices, including increasingly autonomous—or “agentic”—systems.
This is not final guidance or a proposed rule. It is an invitation to help shape the regulatory framework before that framework is established.
As someone who has spent years working at the intersection of artificial intelligence, medical technology, and high-acuity clinical care, I found the central premise compelling: the performance of medical AI cannot be reduced to a single benchmark score.
A system must demonstrate clinical knowledge, sound reasoning, appropriate communication, safety-critical behavior, and reliable performance across diverse patient populations and realistic clinical conditions. Agentic systems may also need to demonstrate that they can plan, use external tools, and complete multistep tasks without moving beyond their intended purpose or safety boundaries.
One of the most important issues raised by the FDA is balance.
An AI system can fail by acting when it should not—but it can also fail by refusing to act when a request falls within its intended use. Likewise, under-escalating a serious condition can delay necessary care, while over-escalating can create unnecessary interventions, increase the burden on healthcare systems, and eventually erode trust.
That distinction matters.
In high-acuity environments, safety is not achieved by sending every decision back to an already overloaded clinician or producing an endless stream of warnings. When clinical teams are already managing alert fatigue and constant interruptions, indiscriminate escalation may teach them to ignore the system at precisely the moment it is needed most.
The FDA is also considering whether the final, user-facing product should be evaluated as it is actually configured and intended to be deployed—not merely the underlying foundation model or an isolated software component.
Passing a laboratory benchmark is not the same as demonstrating safety and effectiveness within a real clinical workflow.
At PathFree Technologies, this principle aligns closely with how we think about the responsible development of medical AI. Technology must augment clinical judgment, support timely and informed decisions, and make critical workflows more reliable. It should not create another layer of distraction, uncertainty, or noise.
Public comments are being accepted under docket FDA-2026-N-7874 through October 19, 2026. Clinicians, nurses, patients, researchers, medical-device developers, and healthcare safety leaders all have an opportunity to contribute.
If you work in medical AI, clinical technology, or patient safety, I encourage you to read the discussion paper and make your perspective known.
What standards do you believe medical AI should be required to meet before it is trusted in real-world patient care?
Please share this with someone whose experience should be represented in this important discussion.
